Global Cloud-based Drug Discovery Platforms Market 2023: Pharmaceutical Vendors Projected to be the Most Attractive End User Segment | PMR

The cloud-based drug discovery platform market is expected to grow significantly in 2022 due to the increasing demand for innovative and cost-effective solutions in the pharmaceutical industry. These platforms provide a range of services including data management, computational modeling, and virtual screening, which can help accelerate the drug discovery process.

Request For Free Sample Report of "Cloud-based Drug Discovery Platform Market"@ https://www.persistencemarketresearch.com/samples/11020

One of the key drivers of the cloud-based drug discovery platform market is the growing adoption of cloud computing in the pharmaceutical industry. Cloud-based platforms enable pharmaceutical companies to access and analyze large amounts of data quickly and efficiently, which can improve the accuracy and speed of drug discovery. Additionally, these platforms can be accessed remotely, which makes it easier for researchers to collaborate and share data with colleagues.

Companies

IBM Corporation
Tata Consultancy Services Limited
SAS Institute Inc.
BioXcel Corporation
Cloud Pharmaceuticals Inc.
WuXi AppTec (Sanghai) Co. Ltd.
Dassault System
Acelot, Inc.

Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/11020

Another factor driving the growth of the cloud-based drug discovery platform market is the increasing demand for personalized medicine. These platforms can be used to analyze patient-specific data and predict which therapies are most likely to be effective, which can improve treatment outcomes and reduce the risk of adverse side effects.

Overall, the cloud-based drug discovery platform market is expected to experience strong growth in 2022 and beyond due to the increasing adoption of these solutions by pharmaceutical companies and the demand for more personalized and effective therapies.

Pharmaceutical Vendors segment to lead the global market in terms of revenue share throughout the forecast period

Our forecasts indicate that the Pharmaceutical Vendors segment will remain the leading end user segment during the forecast period 2017 to 2025, estimated to reach a market valuation of US$ 1,625.0 Mn by the end of the forecast period in 2025, with a CAGR of 13.4%.

In terms of CAGR though, the Contract Research Organizations segment is expected to stand first, registering a growth rate of 13.8% during the eight year period. The Contract Research Organizations segment is also anticipated to witness high Y-o-Y growth rates throughout the forecast period.

Request Customization @ https://www.persistencemarketresearch.com/request-customization/11020

Market Taxonomy

By End User
Pharmaceutical Vendors
Biotech Vendors
Contract Research Organizations
Others

By Region
North America
Latin America
Europe
Asia Pacific
MEA

For More Premium Insights, Check out the Link:

Psoriasis Drugs Market - https://www.prnewswire.com/news-releases/psoriasis-drugs-market-is-predicted-to-progress-at-a-cagr-of-6-5-to-reach-a-valuation-of-us-21-48-bn-by-2031--301482350.html

Botulinum Toxin Market - https://www.prnewswire.com/news-releases/botulinum-toxin-market-is-set-to-expand-at-a-cagr-of-6-9-and-reach-a-valuation-of-us-10-7-bn-by-2031--301477267.html

Wearable Injectors Market - https://www.prnewswire.com/news-releases/wearable-injectors-market-expanding-at-a-cagr-of-around-11-8-over-the-forecast-period-2021-2031---persistence-market-research-301477856.html

Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353
sales@persistencemarketresearch.com

About Us

Persistence Market Research's Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.

This release was published on openPR.